QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Karyopharm Therapeutics Inc. (KPTI)

Healthcare

No action
Fundamental
1
Sentiment
1
Technical
1

Do Nothing: fundamentalScore 1 and qualitativeScore 1 both sit below the required floor of 3 (Chapter 11 with a prepackaged plan cancelling existing equity for no distribution, plus Nasdaq trading suspension from 2026-11-11), and the chart independently fails — technicalScore 1, price 0.04 below SMA20 0.37/SMA50 1.00/SMA200 5.85, avgDollarVolume20 $4.12M below the $5M floor, recent 3-session regular-session dollar volume ~$0.58M below the $1.5M floor, and max overnight gap 35.7% above the 5% ceiling; no breakout stop qualifies (only settled level above spot is the 0.0441 high, inside one $0.14 ATR of noise) and no pullback limit qualifies (52-week low with no support beneath and countertrend below SMA50 with MACD < 0).

Analysis as of 2026-11-10· more than 2 trading days ago

Company overview

Karyopharm Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing drugs that disrupt nuclear export pathways, primarily for cancer treatment. Their leading product, XPOVIO, is approved for multiple myeloma and diffuse large B-cell lymphoma. The company is based in Newton, Massachusetts.

Fundamental

very weak
Fundamental1
Bankruptcy proceedings

Karyopharm's Chapter 11 filing cancels all equity, making it uninvestable.

Karyopharm filed a prepackaged Chapter 11 on 2026-11-02; the plan cancels all existing common and preferred equity with no distribution, the company expects a complete loss for shareholders, and Nasdaq trading is suspended from 2026-11-11. With $65.1M of cash against $441.5M of liabilities, going-concern language in both the 10-K and the 10-Q, and roughly $366M of secured debt accelerated by the filing, the equity is uninvestable.

Sentiment

very weak
Sentiment1
Negative sentiment

Sentiment is sharply negative following the Chapter 11 filing and Nasdaq delisting notice.

Dominant catalyst is the announced 2026-11-02 Chapter 11 filing wrapped around a prepackaged, stalking-horse merger with Ayrmid Ltd. (confidence: announced) that cancels all existing equity for no distribution, with a Nasdaq delisting determination and trading suspension from 2026-11-11 (announced). The sentiment delta is determinate and sharply negative — media polarity deteriorates from polarity_score ≈ +0.12 in the 2026-08-12 → 2026-10-11 baseline to ≈ −0.55 across 2026-10-27 → 2026-11-10 — and a severe red-flag cap applied on two counts (an explicit going-concern/auditor-doubt conclusion and an imminent value-extinguishing catalyst inside the horizon).

Technical

very weak
Technical1
Broken structure

The stock trades far below all moving averages in a strong downtrend with no reversal signals.

Broken structure in an unmitigated waterfall. At $0.04 the stock sits ~89% below its SMA20 ($0.37), ~96% below its SMA50 ($1.00) and ~99% below its SMA200 ($5.85), with EMA9 $0.21 and EMA21 $0.43 stacked far overhead and the 2026-11-09 VWAP at $0.0397. RSI14 28.53 and Williams %R -99.48 are pinned at oversold extremes but show no positive divergence, MACD is negative (line -0.27, signal -0.27, histogram 0.00) and ADX14 42.22 confirms a powerful directional trend that is DOWN, not up. ATR14 $0.14 equals ~350% of the share price after the collapse from $0.90 (2026-10-30) to $0.04; StdDev20 is $0.24. Chart score is 1 (bearish/broken). Trade is blocked by the fundamentalScore 1 and qualitativeScore 1 floors (Chapter 11 with existing equity cancelled for no distribution, Nasdaq trading suspended from 2026-11-11), the $5M average-dollar-volume floor ($4.12M), the $1.5M recent 3-session regular-session liquidity floor (~$0.58M) and the 5% overnight-gap ceiling (max gap 35.7%).

You’re looking at 2026-11-10 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.